KRTX - Karuna Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
69.50
-4.01 (-5.46%)
As of 11:12AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close73.51
Open74.52
Bid69.00 x 1000
Ask69.25 x 1000
Day's Range68.47 - 74.52
52 Week Range11.24 - 152.00
Volume265,088
Avg. Volume582,460
Market Cap1.7B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Karuna Therapeutics Shares March Higher, Can It Continue?
    Zacks

    Karuna Therapeutics Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor Karuna Therapeutics

  • TEST Business Wire Releases

    Karuna Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Andrew Miller, Ph.D., founder and chief operating officer at Karuna, will present and host investor meetings at the Piper Jaffray 31st Annual Healthcare Conference being held at the Lotte New York Palace in New York, NY. The Company is scheduled to present on Thursday, December 5, 2019, at 12:30 p.m. ET.

  • Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
    Zacks

    Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More

    Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

  • Here's Why This Biotech Stock Has Septupled In Value Over Two Days
    Investor's Business Daily

    Here's Why This Biotech Stock Has Septupled In Value Over Two Days

    Karuna stock has nearly septupled in value over two days after the biotech company's schizophrenia treatment succeeded in a midstage test. The drug proved itself over five weeks.

  • Company News For Nov 19, 2019
    Zacks

    Company News For Nov 19, 2019

    Companies in the news are: KRTX, EROS, CARO, SNNA

  • Benzinga

    The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • Dow Jones Futures: Can Software Rejoin Stock Market Rally? Apple Event Planned; These Stocks Are Moving On News
    Investor's Business Daily

    Dow Jones Futures: Can Software Rejoin Stock Market Rally? Apple Event Planned; These Stocks Are Moving On News

    Stock futures: Can software rejoin the market rally as Paylocity breaks out? ServiceNow added to gains late. Apple, Karuna Therapeutics, Roku and ZTO Express moved on news too.

  • MarketWatch

    Karuna Therapeutics' stock more than triples after upbeat trial results of schizophrenia treatment

    Shares of Karuna Therapeutics Inc. more than tripled (up 254%) in active trading, to lift the biopharmaceutical company's market capitalization to well above $1 billion, after a phase 2 trial of its schizophrenia treatment met its primary endpoint. Trading volume ballooned to 6.5 million shares, compared with the full-day average of about 70,000 shares. The company said its KarXT port the treatment of acute psychosis in schizophrenia patients demonstrated a "statistically significant and clinically meaningful" reduction in total positive and negative syndrome scale (PANSS) score compared with a placebo. KarXT was also well tolerated. "With this information, and following our anticipated end-of-Phase 2 meeting with the FDA in the second quarter of 2020, we will work to initiate a Phase 3 clinical trial of KarXT in patients with schizophrenia by the end of 2020," said Chief Medical Officer Stephen Brannan. The stock, which went public on June 28 at an initial-public-offering price of $16, has nearly tripled (up 182%) over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 5.5% and the S&P 500 has rallied 7.9%.

  • GuruFocus.com

    Karuna Therapeutics Inc (KRTX) President & CEO Steven M Paul Bought $230,400 of Shares

    President & CEO of Karuna Therapeutics Inc (NASDAQ:KRTX) Steven M Paul bought 10,000 shares of KRTX on 06/28/2019 at an average price of $23.04 a share.

  • Benzinga

    Karuna Therapeutics Opens Above IPO Price

    Karuna Therapeutics, Inc. (NASDAQ: KRTX ) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share. Karuna focuses on developing novel therapies to address disabling ...

  • Benzinga

    Karuna Therapeutics IPO: What You Need To Know

    Biotech investors seeking a play on the lucrative, yet hard-to-crack central nervous system disorder therapy market have an opportunity this week.  The IPO Terms Boston, Massachusetts-based Karuna Therapeutics, ...